Orum Therapeutics, a Korean biotechnology developer targeting cancer and rare diseases, has secured a $30 million Series B round from a group including IMM Investment and InterVest.
Singapore-based healthcare platform Novena Global Lifecare has completed a $350 million merger with Xingkedou, a VC-backed Chinese hair salon operator that specializes in fast turnaround services.
Melissa Kang helped raise Morgan Stanley’s first global impact fund before striking out on her own with Jupiter Impact Partners. She explains why Southeast Asia should prove fertile ground for the strategy
Miaoshou Doctor, a Chinese online healthcare services platform that has expanded into the offline pharmacy space, has completed its extended Series C funding round, having achieved a post-deal valuation of more than RMB7 billion ($1 billion).
EQT Partners has made a take-private offer for Singapore-listed hospital operator Health Management International (HMI) that values the company at S$611 million ($449 million).
Synyi, a Chinese artificial intelligence (AI) start-up that targets hospitals, has taken its total fundraising to RMB550 million ($80 million) following a RMB250 million Series C led by Tencent Holdings and featuring Sinopharm Capital.
The International Finance Corporation (IFC) and Switzerland-based family office Corisol Holdings have led a $70 million Series D round for Indian online healthcare services platform operator 1mg Technologies.
China’s 6 Dimensions Capital and Yonghua Capital have joined a $22 million Series C round for US-based Ultivue that will help the medical technology developer expand into Asia.
Weimai plans to leverage a fresh $100 million funding round to bring new technologies to Chinese hospitals. This will include a growing focus on services outside the public health system
IIFL Asset Management (IIFL AMC) has acquired a majority stake in Infigo Life Sciences, operator of a chain of eyecare centers in India.
China-based GPs Sinopharm Capital and Cedarlake Capital have announced a $20 million investment in Singapore-based healthcare platform Novena Global Lifecare, along with a strategic partnership for a $150 million fund that will support Southeast Asian...
IDG Capital has led a $100 million funding round for Weimai, a Chinese healthcare-focused big data platform that helps hospitals and clinics in lower-tier cities automate everything from appointment registration to medical records management.
Australian alternative asset manager Quintet Partners has invested an undisclosed amount in Exact Radiology, a private equity-backed operator of a chain of diagnostic imaging clinics in Queensland.
Newly established Japanese venture capital firm Catalys Pacific has launched its debut fund with a view to raise $100 million for investments in early-stage life science start-ups globally.
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Sovereign wealth funds are dialing up their direct exposure to technology and healthcare start-ups, but this trend is accompanied by a varied collection of co-investment models
Oncologie, a cancer drug developer with bases in Shanghai and Boston, has secured $80 million in Series B funding led by Nan Fung Life Sciences and Pivotal Bioventure Partners China.
US and China-focused healthcare investor Vivo Capital has raised $1.28 billion for its ninth private equity fund. The predecessor vehicle closed at $750 million in 2015.
Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has raised a $74 million Series B round led by SDIC Fund Management and healthcare specialist Sherpa Healthcare Partners.
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, saw its stock drop almost 20% on debut following a HK$1.23 billion ($157 million) IPO in Hong Kong.
Chinese venture capital firm Legend Capital has appointed Asia PE industry veteran Piau-Voon Wang (pictured) as a managing director and COO as part of efforts to institutionalize operations and diversify its LP base.
Frontage Holdings, a China-based contract research organization (CRO), has raised HK$1.61 billion ($205.1 million) in its Hong Kong IPO, having received support from several private equity investors.
Mekong Capital has spent the last two years helping Pharmacity bring Vietnam’s outdated retail pharmacy market into the modern age. Now the company is preparing to fend off a wave of copycats
Chinese biopharmaceutical developer Alphamab Oncology has completed a $60 million Series B round led by US and UK-based investor Hudson Bay Capital Management.